ArticleJournal of virology2002
Functional interaction between JC virus late regulatory agnoprotein and cellular Y-box binding transcription factor, YB-1.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 65 citations in OpenAlex.
- Target-specific peptides for BK virus agnoprotein identified through phage display screening: advancing antiviral therapeutics.Scientific reports · 2025Article
- JC virus small tumor antigen promotes S phase entry and cell cycle progression.Tumour virus research · 2024Article
- The oncogenic roles of JC polyomavirus in cancer.Frontiers in oncology · 2022Review
- Expression of novel proteins by polyomaviruses and recent advances in the structural and functional features of agnoprotein of JC virus, BK virus, and simian virus 40.Journal of cellular physiology · 2019Review
- Structure-based release analysis of the JC virus agnoprotein regions: A role for the hydrophilic surface of the major alpha helix domain in release.Journal of cellular physiology · 2018Article
- Nuclear Magnetic Resonance Structure of the Human Polyoma JC Virus Agnoprotein.Journal of cellular biochemistry · 2017Article
- The DNA damage response promotes polyomavirus JC infection by nucleus to cytoplasm NF- kappaB activation.Virology journal · 2017Article
- Review on the role of the human Polyomavirus JC in the development of tumors.Infectious agents and cancer · 2017Review
- Immune suppression of JC virus gene expression is mediated by SRSF1.Journal of neurovirology · 2016Article
- Emerging From the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses.Journal of cellular physiology · 2016Review
- JC virus nucleotides 376-396 are critical for VP1 capsid protein expression.Journal of neurovirology · 2015Article
- Agnoprotein of polyomavirus BK interacts with proliferating cell nuclear antigen and inhibits DNA replication.Virology journal · 2015Article
- Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy.Human gene therapy · 2014Article
- Nuclear magnetic resonance structure revealed that the human polyomavirus JC virus agnoprotein contains an α-helix encompassing the Leu/Ile/Phe-rich domain.Journal of virology · 2014Article
- A novel recombinant papillomavirus genome enabling in vivo RNA interference reveals that YB-1, which interacts with the viral regulatory protein E2, is required for CRPV-induced tumor formation in vivo.American journal of cancer research · 2014Article
- Article
- Agnogene deletion in a novel pathogenic JC virus isolate impairs VP1 expression and virion production.PloS one · 2013Article
- Article
- Agnoprotein of mammalian polyomaviruses.Virology · 2012Review
- Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.Clinical microbiology reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human polyomavirus JC virus (JCV) is a causative agent of progressive multifocal leukoencephalopathy which results from lytic infection of glial cells. Although significant progress has been made in understanding the regulation of JCV gene transcription, the mechanism(s) underlying the viral lytic cycle remains largely unknown. We recently reported that the JCV late auxiliary Agnoprotein may have a regulatory role in JCV gene transcription and replication. Here, we investigated its regulatory function in viral gene transcription through its physical and functional interaction with YB-1, a cellular transcription factor which contributes to JCV gene expression in glial cells. Time course studies revealed that Agnoprotein is first detected at day 3 postinfection and that its level increased during the late stage of the infection cycle. Agnoprotein is mainly localized to the cytoplasmic compartment of the infected cell, with high concentrations found in the perinuclear region. While the position of Agnoprotein throughout the infection cycle remained relatively unaltered, the subcellular distribution of YB-1 between the cytoplasm and nucleus changed. Results from coimmunoprecipitation and glutathione S-transferase pull-down experiments revealed that Agnoprotein physically interacts with YB-1 and that the amino-terminal region of Agnoprotein, between residues 1 and 36, is critical for this association. Further investigation of this interaction by functional assays demonstrated that Agnoprotein negatively regulates YB-1-mediated gene transcription and that the region corresponding to residues 1 to 36 of Agnoprotein is important for the observed regulatory event. Taken together, these data demonstrate that the interaction of the viral late regulatory Agnoprotein and cellular Y-box binding factor YB-1 modulates transcriptional activity of JCV promoters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.